



# TIRmed Enters into Collaboration with Bachem to Advance Oligonucleotide Therapy for Atopic Dermatitis

TIRmed Pharma, a biotechnology company developing next-generation treatments for autoimmune skin diseases, has entered into a collaboration with Bachem, a leading company in advanced oligonucleotide manufacturing. The collaboration covers process development and manufacturing of TIR-01, the active pharmaceutical ingredient in TIRmed's novel therapy for atopic dermatitis (eczema). This marks an important step toward upcoming clinical trials.



TIRmed Pharma is advancing a next-generation treatment for atopic dermatitis, designed to offer patients effective treatment with fewer side effects and simpler administration. The treatment targets the root causes of the disease rather than merely alleviating symptoms. In preclinical studies, five topical applications over two weeks have resulted in up to 15 months of sustained relief.

As part of its preclinical program, TIRmed Pharma has partnered with Bachem to establish high-quality production processes for TIR-01, an oligonucleotide-based substance. With its expertise in oligonucleotide manufacturing, Bachem contributes essential capabilities for GMP development, ensuring stability, consistency, and regulatory compliance ahead of clinical trials.

"The collaboration with Bachem is an important milestone in our efforts to advance our candidate drug to the clinic. Through this collaboration, we gain access to world-leading manufacturing expertise and strengthen the foundation for offering patients a more durable treatment option," says Leo Holmgren, CEO of TIRmed Pharma.

**For more information, please contact:**  
Leo Holmgren, CEO

Phone: +46 70 049 18 42

Email: [leo.holmgren@tirmedpharma.com](mailto:leo.holmgren@tirmedpharma.com)

### **About TIRmed Pharma**

TIRmed Pharma is a biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on atopic dermatitis (eczema). The company's drug candidate, TIR-C, is a topical oligonucleotide-based treatment that regulates immune responses and targets the disease's underlying mechanisms. Promising preclinical results support its potential to provide long-lasting relief and reduce treatment burden. Building on expertise in immunology and drug development, the company is pioneering new solutions in dermatological immunotherapy to enable more targeted and effective treatment options. TIRmed Pharma is headquartered in Stockholm, Sweden. For more information, visit [tirmedpharma.com](http://tirmedpharma.com) and follow TIRmed on [LinkedIn](#).

### **About Bachem**

Bachem is a leading, innovation-driven company specialized in the development and manufacturing of peptides and oligonucleotides. With over 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. For more information, visit <http://www.bachem.com/>.